Patents Assigned to GUANGZHOU SINOGEN PHARMACEUTICAL CO., LTD

Applications of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer

Patent number: 11771721

Abstract: Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer.

Type: Grant

Filed: March 29, 2018

Date of Patent: October 3, 2023

Assignee: GUANGZHOU SINOGEN PHARMACEUTICAL CO., LTD

Inventors: Allan Zijian Zhao, Yan Lin, Sujin Zhou, Fanghong Li
Application of genetically engineered bacteria VNP20009-M in preparing drug for treating malignant sarcoma

Patent number: 11324781

Abstract: Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating malignant sarcoma.

Type: Grant

Filed: March 29, 2018

Date of Patent: May 10, 2022

Assignee: GUANGZHOU SINOGEN PHARMACEUTICAL CO., LTD.

Inventors: Allan Zijian Zhao, Yan Lin, Sujin Zhou, Fanghong Li
Use of genetically engineered bacterium of attenuated in for treating liver cancer

Patent number: 11318172

Abstract: Provided is use of a genetically engineered bacterium of attenuated Salmonella typhimurium for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Type: Grant

Filed: October 9, 2020

Date of Patent: May 3, 2022

Assignee: GUANGZHOU SINOGEN PHARMACEUTICAL CO., LTD

Inventors: Allan Zijian Zhao, Sujin Zhou, Yan Lin, Zhenggang Zhao, Fanghong Li

Applications of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer

Application of genetically engineered bacteria VNP20009-M in preparing drug for treating malignant sarcoma

Use of genetically engineered bacterium of attenuated in for treating liver cancer